Large-vessel giant cell arteritis: a cohort study.

Rheumatology (Oxford) 2015 Mar 5;54(3):463-70. Epub 2014 Sep 5.

Division of Rheumatology, Department of Medicine, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, Division of Rheumatology, Department of Medicine, Division of Biostatistics, Department of Health Sciences Research and Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Objective: The aim of this study was to compare baseline variables, treatment and outcomes in patients with large-vessel GCA (LV-GCA), primarily of the upper extremities, with those with cranial disease (C-GCA).

Methods: All patients >50 years of age with radiographic evidence of subclavian LV-GCA diagnosed between 1 January 1999 and 31 December 2008 were identified and compared with those with biopsy-positive C-GCA diagnosed in the same period.

Results: The study included 120 LV-GCA patients and 212 C-GCA patients. Compared with C-GCA, patients with LV-GCA were younger [68.2 years (s.d. 7.5) vs 75.7 (7.4), P < 0.001] and had longer duration of symptoms at GCA diagnosis (median 3.5 vs 2.2 months, P < 0.001). A history of PMR was more common in LV-GCA patients (26% vs 15%, P = 0.012), but a smaller proportion had cranial symptoms (41% vs 83%, P < 0.001) and vision loss (4% vs 11%, P = 0.035). ACR classification criteria for GCA were satisfied in 39% of LV-GCA patients and 95% of C-GCA patients (P < 0.001). Compared with C-GCA, patients with LV-GCA had more relapses (4.9 vs 3.0/10 person-years, P < 0.001), higher cumulative corticosteroid (CS) doses at 1 year [11.4 g (s.d. 5.9) vs 9.1 (s.d. 3.7), P < 0.001] and required longer treatment (median 4.5 vs 2.2 years, P < 0.001).

Conclusion: Although patients with LV-GCA had a lower rate of vision loss, they had a higher relapse rate and greater CS requirements. The ACR criteria for GCA are inadequate for the classification of patients with LV-GCA.

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keu329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425829PMC
March 2015
6 Reads

Publication Analysis

Top Keywords

c-gca patients
16
patients lv-gca
16
lv-gca patients
12
patients
11
lv-gca
9
vision loss
8
compared c-gca
8
criteria gca
8
c-gca
5
patients 26%
4
26% 15%
4
common lv-gca
4
pmr common
4
months 0001
4
0001 history
4
history pmr
4
15% 0012
4
0012 smaller
4
83% 0001
4
0001 vision
4

References

(Supplied by CrossRef)
Article in New England Journal of Medicine
Salvarani et al.
New England Journal of Medicine 2002
Article in Arthritis and rheumatism
Nuenninghoff et al.
Arthritis and rheumatism 2003
Article in Current opinion in rheumatology
Silva et al.
Current opinion in rheumatology 2006
Article in Annals of Internal Medicine
KLEIN et al.
Annals of Internal Medicine 1975
Article in Arthritis and rheumatism
Brack et al.
Arthritis and rheumatism 1999
Article in The Journal of Rheumatology
The Journal of Rheumatology 2009
Article in Lancet
Salvarani et al.
Lancet 2008
Article in Seminars in arthritis and rheumatism
Lie et al.
Seminars in arthritis and rheumatism 1995
Article in Rheumatology
Schmidt et al.
Rheumatology 2008
Article in Rheumatology
Rheumatology 2012
Article in Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases 2010

Similar Publications